3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
2
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Pancreatic Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Rectal Neoplasms
6
Colorectal Neoplasms
6
Breast Neoplasms
6
Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Stomach Neoplasms
3
Oligodendroglioma
3
Mouth Neoplasms
3
Lung Neoplasms
3
Glioma
3
Esophageal Neoplasms
3
Astrocytoma
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Meningioma
2
Melanoma
2
Gliosarcoma
2
Glioma, Subependymal
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Adenocarcinoma Of Esophagus
2
Xerostomia
1
Interventions
Cyclophosphamide
12
aldesleukin
9
fludarabine
8
fludarabine phosphate
7
pembrolizumab
6
Ipilimumab
5
Interleukin-2
5
Nivolumab
4
dabrafenib
2
Vemurafenib
2
Biopsy
2
Aminolevulinic Acid
2
varlilumab
1
trametinib
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
glembatumumab vedotin
1
eprenetapopt
1
epacadostat
1
encorafenib
1
cemiplimab
1
cabozantinib
1
binimetinib
1
bempegaldesleukin
1
abobotulinumtoxinA
1
X-Rays
1
Tranexamic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Skin Neoplasms
×
Surgical Procedures, Operative
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled